JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) EV-to-EBIT : -0.37 (As of May. 15, 2024)

JW (Cayman) Therapeutics Co EV-to-EBIT Chart

JW (Cayman) Therapeutics Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial						-3.96	-	-0.59	-	-0.22

Competitive Comparison of JW (Cayman) Therapeutics Co's EV-to-EBIT

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

JW (Cayman) Therapeutics Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's EV-to-EBIT falls into.

JW (Cayman) Therapeutics Co EV-to-EBIT Calculation

JW (Cayman) Therapeutics Co's EV-to-EBIT for today is calculated as:

JW (Cayman) Therapeutics Co's current Enterprise Value is $41.33 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-111.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co  (OTCPK:JWCTF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

JW (Cayman) Therapeutics Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

JW (Cayman) Therapeutics Co's Enterprise Value for the quarter that ended in Dec. 2023 was $13.96 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. JW (Cayman) Therapeutics Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-111.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description